The analyses of ACCORD suggest a cardiovascularbenefit of the lower BP target in those randomized to stan-dard glucose control but no benefit in those randomized tointensive glucose control, though the data remain hypothesis-generating.8Based on these and other data, the WG feels thatcardiovascular benefits of intensive BP-lowering cannot beexcluded in patients with concomitant diabetes and CKD andthat a large randomized trial addressing this issue iswarranted.